Full-Time

Senior Research Scientist

Machine Learning, BioFMs

Deep Genomics

Deep Genomics

51-200 employees

AI-driven RNA-based drug discovery platform

Compensation Overview

$175k - $200k/yr

+ Stock Ownership

Toronto, ON, Canada

Hybrid

PhD

Category
AI & Machine Learning (1)
Required Skills
LLM
Neural Networks
PyTorch
Machine Learning

Get referred to Deep Genomics

See people who can refer or advise you

Requirements
  • PhD (or evidence of equivalent level of expertise) with a strongly distinguished research focus in Computational Biology, Machine Learning, Computer Science, or a related quantitative field.
  • Deep understanding of modern deep learning and the creative building of foundation models, including CNNs, Transformers, and related sequence models (e.g., state-space models) specifically tailored for biological or genomic sequence data.
  • A demonstrated track record of building and scaling AI models for complex biological datasets (e.g., single-cell genomics, DNA/RNA sequences) from initial conception to production.
  • Proven ability to implement, train, and debug highly-performant deep learning models using frameworks like PyTorch.
  • Experience working with massive datasets and a deep understanding of the engineering and algorithmic challenges associated with scale.
  • Excellent communication skills, capable of discussing complex ideas seamlessly with both ML engineers and biological domain experts.
Responsibilities
  • Lead the creative research, architecture design, and training of Biological Foundation Models (BioFMs), on massive-scale genomic, transcriptomic, and single-cell datasets.
  • Collaborate closely with computational biologists and drug developers to integrate deep biological priors directly into model architectures and training objectives, ensuring our BioFMs capture fundamental and scientifically meaningful representations.
  • Rigorously implement, train, debug, and evaluate large-scale models to demonstrate scientific validity and drive progress on frontier problems in human health and genetic medicines.
  • Stay current with advancements in machine learning and computational biology research, identifying cross-disciplinary applications to solve real-world challenges.
  • Mentor junior scientists and engineers, fostering a culture of technical excellence and scientific curiosity through leadership and high-quality code review.
  • Share research findings through internal presentations and contribute to the scientific community via publications in top-tier venues.
Desired Qualifications
  • A strong track record of impactful research demonstrated through first-author publications in high-impact scientific journals (e.g., Nature, Science, Cell) or top-tier ML/CompBio conferences (e.g., NeurIPS, ICML, ICLR, ISMB, RECOMB).
  • 2+ years of relevant post-graduate experience at a leading industrial R&D lab or in a highly competitive academic environment building genomics AI.
  • Experience technically leading projects or mentoring junior researchers/engineers.
  • Proficiency with cloud computing platforms (e.g., GCP) for large-scale model training and experimentation.
  • Contributions to open-source projects demonstrating the ability to solve complex research problems in ML or computational biology.

Deep Genomics uses AI to speed up drug discovery by studying RNA biology and how genetic variants affect gene expression. Its main product, the AI Workbench, analyzes genomic data to identify novel drug targets and potential therapies for genetic diseases. It differentiates itself by focusing on RNA-level mechanisms and expanding its target discovery capabilities across versions. The goal is to provide a license-ready platform that yields actionable targets for collaboration or internal development, accelerating therapies for patients with genetic conditions.

Company Size

51-200

Company Stage

Series C

Total Funding

$236.8M

Headquarters

Toronto, Canada

Founded

2014

Get referred to Deep Genomics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BioMarin collaboration in March 2026 validates Deep Genomics for rare-disease dealmaking.
  • July 2026 board upgrade strengthens fundraising, partnering, and clinical-development execution.
  • The company still markets active jobs, implying continued capital access and operating momentum.

What critics are saying

  • BioMarin and Deep Genomics partnership leaves value capture with BioMarin in 2026.
  • No public clinical readouts followed the 2023 four-program clinic goal, weakening credibility.
  • AI drug discovery remains existentially fragile if Deep Genomics misses first-in-human wins by 2027.

What makes Deep Genomics unique

  • BioFM and BigRNA target RNA biology, not generic target discovery.
  • Deep Genomics pairs genomics scientists with AI engineers in Toronto and Cambridge.
  • Board chairs Thong Q. Le and Paul Sekhri signal serious life-sciences governance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-3%
Deep Genomics
Jul 23rd, 2026
Deep Genomics appoints Thong Q. Le as Chair of the Board of Directors.

Deep Genomics appoints Thong Q. Le as Chair of the Board of Directors. July 23, 2026 CAMBRIDGE, Mass. & TORONTO - Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of Thong Q. Le as chair of its Board of Directors. "Since joining our Board in 2025, Thong has been a trusted advisor and a strong advocate for our vision," said Brendan Frey, Founder and Chief Innovation Officer of Deep Genomics. "He brings a fresh energy and deep experience supporting the life sciences industry to the role, making him exceptionally well positioned to lead our Board as Deep Genomics continues to advance AI-driven drug discovery." Mr. Le joined the Deep Genomics Board of Directors in 2025, bringing more than 20 years of experience investing in the life sciences sector. Throughout his career, he has guided high-impact investments and supported deal-making efforts that have driven meaningful health outcomes. He also serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Gates Foundation, and chairman of Accelerator Life Science Partners (ALSP), a venture capital firm dedicated to building next-generation life science companies. As Chair, Mr. Le will help guide Deep Genomics through its next phase of growth as the company advances its internal pipeline toward clinical development, expands strategic collaborations, and further establishes its leadership at the intersection of AI, genomics, and drug discovery. "I'm honored to take on the role of Chair of the Board of Directors at such an exciting time for Deep Genomics and the broader TechBio industry," said Le. "Deep Genomics has built a unique platform and world-class team leading at the intersection of AI and biology. I look forward to continuing my work alongside the company as it advances its mission to transform how medicines are discovered and developed." Mr. Le succeeds Chip Baird, who served as Chair of the Board for the past three years. Mr. Baird will continue to support Deep Genomics as a non-executive director and will serve as Chair of the Audit Committee. To learn more about Deep Genomics' work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/. About Deep Genomics Deep Genomics is a fully integrated AI-first TechBio company pioneering a new approach to drug discovery with its Biological Foundation Model (BioFM) platform. At the intersection of genomics, drug development, and AI, Deep Genomics brings together a world-class team of scientists, engineers, and researchers to solve complex biological challenges at scale and accelerate the discovery and development of genetic medicines to improve patient outcomes. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow Deep Genomics Inc. on LinkedIn and Twitter.

Deep Genomics
Oct 6th, 2025
Thong Q. Le and Paul Sekhri Join Board of Directors at Deep Genomics

Thong Q. Le and Paul Sekhri join Board of Directors at Deep Genomics. Pictured: Thong Q. Le (left) and Paul Sekhri (right), the newest members of the Board of Directors for Deep Genomics Cambridge, Mass. / Toronto, CA - October 6, 2025 - Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic medicines with its AI foundation model platform, today announced the appointment of respected business leaders Thong Q. Le and Paul Sekhri to its Board of Directors. "We feel incredibly lucky to have the talents of Thong and Paul join our Board of Directors", said Brian O'Callaghan, Chief Executive Officer of Deep Genomics. "Their collective decades of experience shaping the life sciences and biotechnology industry will be invaluable as we continue towards our mission of delivering AI-powered genetic medicines to patients." Thong Q. Le brings more than two decades of investment experience in the life sciences industry, with a strong track record of making impactful investments that improve lives, shaping effective investment strategies and aiding deal-making processes. Mr. Le currently serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Gates Foundation. Mr. Le also serves as chairman of Accelerator Life Science Partners (ALSP), a venture capital firm focused on developing next-generation life science companies. He has served as a director, founding president and CEO of more than a dozen ALSP portfolio companies, including Petra Pharma, Rodeo Therapeutics and Lodo Therapeutics. Mr. Le currently serves on several private biotech and nonprofit organization boards. "In my time working with this industry, I've seen firsthand how the right combination of science, technology and leadership can transform what's possible in drug discovery," said Mr. Le. "Deep Genomics has all of those ingredients, and I'm thrilled to have this opportunity to help guide its continued growth." Paul Sekhri is the current Chair, President and CEO of vTv Therapeutics Inc., Chair of the Board of Resolution Therapeutics, and Executive Chair of Violet Therapeutics Inc., bringing more than 35 years of experience in business development and strategy across top life sciences, pharmaceutical and biotechnology companies. Most recently, he served as President and CEO of eGenesis Inc. and Lycera Corp. Previously, Mr. Sekhri held senior leadership positions at Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals Inc., Ariad Pharmaceuticals and Novartis. He currently serves on the Board of Veeva Systems, AdhereTech Inc., Kayothera; is Chair of Young Concert Artists (YCA), and sits on the Advisory Council of the New York Philharmonic. Mr. Sekhri commented, "I am excited to be joining the Deep Genomics Board at such a pivotal time in therapeutics, and I remain inspired by their ability to advance a new generation of medicines with the power of AI. I look forward to contributing to such important TechBio advancements alongside this talented team." To learn more about Deep Genomics' work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/. About Deep Genomics Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its AI foundation models platform. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-changing genetic medicines to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow Deep Genomics Inc. on LinkedIn and Twitter.

Deep Genomics
Aug 1st, 2025
Deep Genomics CEO Brian O'Callaghan honored as Gold Stevie(R) Award winner in 2025 Stevie Awards for Technology Excellence

Under O'Callaghan's leadership, Deep Genomics launched additional proprietary AI foundation models that work alongside BigRNA, including DeepADAR for RNA editing and REPRESS, which accurately predicts microRNA (miRNA) binding and mRNA degradation directly from RNA sequences.

Medium
Jun 10th, 2025
Deep Genomics secures $180M for AI drug discovery

Deep Genomics, a Canadian biotech company, closed a $180 million Series C funding round led by Softbank, with investments from CPPIB, Fidelity, and others. The company, supported by Amplitude Ventures, uses AI to revolutionize drug discovery, focusing on RNA therapeutics. The funding will expand their AI workbench and pipeline, aiming to advance four programs into the clinic by 2023.

Labiotech
Jan 30th, 2025
Seven Genomics Startups To Look Out For

Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System